Cargando…
Efficacy and safety of cross-linked hyaluronic acid single injection on osteoarthritis of the knee: a post-marketing Phase IV study
PURPOSE: The primary objective of this study was to evaluate the efficacy, safety, and duration of action of viscosupplementation with Crespine(®) Gel over a 9-month period. MATERIALS AND METHODS: The study was a post-marketing Phase IV study. A total of 109 participants with osteoarthritis of the k...
Autores principales: | , , , , |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
Dove Medical Press
2015
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC4396588/ https://www.ncbi.nlm.nih.gov/pubmed/25897212 http://dx.doi.org/10.2147/DDDT.S81524 |
_version_ | 1782366607094317056 |
---|---|
author | Bashaireh, Khaldoon Naser, Ziad Hawadya, Khaled Al Sorour, Sorour Al-Khateeb, Rami Nabeel |
author_facet | Bashaireh, Khaldoon Naser, Ziad Hawadya, Khaled Al Sorour, Sorour Al-Khateeb, Rami Nabeel |
author_sort | Bashaireh, Khaldoon |
collection | PubMed |
description | PURPOSE: The primary objective of this study was to evaluate the efficacy, safety, and duration of action of viscosupplementation with Crespine(®) Gel over a 9-month period. MATERIALS AND METHODS: The study was a post-marketing Phase IV study. A total of 109 participants with osteoarthritis of the knee (grades 1–4) in the tibio–femoral compartment were recruited in Jordan. Data were collected from each participant during the baseline visit. Each participant received Crespine(®) Gel injection, and follow-up visits took place at 3 months, 6 months, and 9 months post-injection. MAIN OUTCOME MEASURE(S): An assessment of participants by phone was conducted at 1 month, 2 months, 4 months, 5 months, 7 months, and 8 months post-injection. Western Ontario and McMaster Universities Arthritis Index questionnaires were completed during each visit. A 72-hour visit questionnaire was used to assess the safety of the injection. Statistical analysis included a two-sided 95% confidence interval for the difference between pain scores across visits, and the percent change from baseline was calculated. MAIN RESULTS: The full analysis included 84 participants who gave their informed consent and finished the necessary baseline and follow-up visits needed to assess efficacy and safety. Peak improvement was noted at 5 months post-injection, when pain and physical performance scores had decreased to 2.60 and 9.90, respectively, and the stiffness score was 0.33. The peak improvement in stiffness was noted at 8 months post-injection, when the stiffness score had decreased to 0.32. Significant improvements were still apparent at 9 months post-injection, when the pain score was 3.36, the stiffness score was 0.42, and the physical performance score was 11.5. All side effects were local and transient, and included pain, swelling, and redness of the knee. Most side effects were treated. CONCLUSION: Hyaluronan should be encouraged as an alternative or adjunct treatment to oral analgesics to reduce their required doses, and delay potential future surgical intervention. |
format | Online Article Text |
id | pubmed-4396588 |
institution | National Center for Biotechnology Information |
language | English |
publishDate | 2015 |
publisher | Dove Medical Press |
record_format | MEDLINE/PubMed |
spelling | pubmed-43965882015-04-20 Efficacy and safety of cross-linked hyaluronic acid single injection on osteoarthritis of the knee: a post-marketing Phase IV study Bashaireh, Khaldoon Naser, Ziad Hawadya, Khaled Al Sorour, Sorour Al-Khateeb, Rami Nabeel Drug Des Devel Ther Original Research PURPOSE: The primary objective of this study was to evaluate the efficacy, safety, and duration of action of viscosupplementation with Crespine(®) Gel over a 9-month period. MATERIALS AND METHODS: The study was a post-marketing Phase IV study. A total of 109 participants with osteoarthritis of the knee (grades 1–4) in the tibio–femoral compartment were recruited in Jordan. Data were collected from each participant during the baseline visit. Each participant received Crespine(®) Gel injection, and follow-up visits took place at 3 months, 6 months, and 9 months post-injection. MAIN OUTCOME MEASURE(S): An assessment of participants by phone was conducted at 1 month, 2 months, 4 months, 5 months, 7 months, and 8 months post-injection. Western Ontario and McMaster Universities Arthritis Index questionnaires were completed during each visit. A 72-hour visit questionnaire was used to assess the safety of the injection. Statistical analysis included a two-sided 95% confidence interval for the difference between pain scores across visits, and the percent change from baseline was calculated. MAIN RESULTS: The full analysis included 84 participants who gave their informed consent and finished the necessary baseline and follow-up visits needed to assess efficacy and safety. Peak improvement was noted at 5 months post-injection, when pain and physical performance scores had decreased to 2.60 and 9.90, respectively, and the stiffness score was 0.33. The peak improvement in stiffness was noted at 8 months post-injection, when the stiffness score had decreased to 0.32. Significant improvements were still apparent at 9 months post-injection, when the pain score was 3.36, the stiffness score was 0.42, and the physical performance score was 11.5. All side effects were local and transient, and included pain, swelling, and redness of the knee. Most side effects were treated. CONCLUSION: Hyaluronan should be encouraged as an alternative or adjunct treatment to oral analgesics to reduce their required doses, and delay potential future surgical intervention. Dove Medical Press 2015-04-08 /pmc/articles/PMC4396588/ /pubmed/25897212 http://dx.doi.org/10.2147/DDDT.S81524 Text en © 2015 Bashaireh et al. This work is published by Dove Medical Press Limited, and licensed under Creative Commons Attribution – Non Commercial (unported, v3.0) License The full terms of the License are available at http://creativecommons.org/licenses/by-nc/3.0/. Non-commercial uses of the work are permitted without any further permission from Dove Medical Press Limited, provided the work is properly attributed. |
spellingShingle | Original Research Bashaireh, Khaldoon Naser, Ziad Hawadya, Khaled Al Sorour, Sorour Al-Khateeb, Rami Nabeel Efficacy and safety of cross-linked hyaluronic acid single injection on osteoarthritis of the knee: a post-marketing Phase IV study |
title | Efficacy and safety of cross-linked hyaluronic acid single injection on osteoarthritis of the knee: a post-marketing Phase IV study |
title_full | Efficacy and safety of cross-linked hyaluronic acid single injection on osteoarthritis of the knee: a post-marketing Phase IV study |
title_fullStr | Efficacy and safety of cross-linked hyaluronic acid single injection on osteoarthritis of the knee: a post-marketing Phase IV study |
title_full_unstemmed | Efficacy and safety of cross-linked hyaluronic acid single injection on osteoarthritis of the knee: a post-marketing Phase IV study |
title_short | Efficacy and safety of cross-linked hyaluronic acid single injection on osteoarthritis of the knee: a post-marketing Phase IV study |
title_sort | efficacy and safety of cross-linked hyaluronic acid single injection on osteoarthritis of the knee: a post-marketing phase iv study |
topic | Original Research |
url | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC4396588/ https://www.ncbi.nlm.nih.gov/pubmed/25897212 http://dx.doi.org/10.2147/DDDT.S81524 |
work_keys_str_mv | AT bashairehkhaldoon efficacyandsafetyofcrosslinkedhyaluronicacidsingleinjectiononosteoarthritisofthekneeapostmarketingphaseivstudy AT naserziad efficacyandsafetyofcrosslinkedhyaluronicacidsingleinjectiononosteoarthritisofthekneeapostmarketingphaseivstudy AT hawadyakhaledal efficacyandsafetyofcrosslinkedhyaluronicacidsingleinjectiononosteoarthritisofthekneeapostmarketingphaseivstudy AT soroursorour efficacyandsafetyofcrosslinkedhyaluronicacidsingleinjectiononosteoarthritisofthekneeapostmarketingphaseivstudy AT alkhateebraminabeel efficacyandsafetyofcrosslinkedhyaluronicacidsingleinjectiononosteoarthritisofthekneeapostmarketingphaseivstudy |